title: Internalization of Bacillus intermedius ribonuclease (BINASE) induces human alveolar adenocarcinoma cell death.
abstract: Ribonuclease (RNase) treatment represents a novel mechanism based approach to anticancer therapy as an alternative to the DNA damaging drugs commonly used in clinical practice. Apart from their ribonucleolytic activity, cytotoxic effects have attracted a considerable attention to RNases because of their potential as selective agents for treatment of certain malignancies. Among these enzymes, Binase, an RNase from Bacillus intermedius, has shown promising results. Here, we have found that binase selectively attacked human A549 alveolar adenocarcinoma cells to trigger an apoptotic response, whereas normal lung epithelial cells LEK were not affected by the ribonuclease. The tumor transformation led to the modification of certain cellular characteristics causing cell sensitivity to binase. Although a general mode for RNases cytotoxicity includes their penetration into the cell, translocation to the cytosol and degradation of ribonucleic acid, many aspects of this process have not been fully elucidated. Our data revealed the following time-dependent changes induced by binase in A549 cells: (a) fast permanent internalization of the enzyme during the first hours of treatment; (b) temporary increase in cellular permeability for macromolecules during the 4-6 h of treatment; (c) apoptotic alterations in population after 24 h and (d) DNA fragmentation and cell death after 72 h of treatment with binase. Elucidation of these molecular strategies used by this promising toxin provides us essential information for the development of new anticancer drugs.
authors.affiliation: Department of Microbiology, Kazan Federal University, Kremlevskaya Str. 18, 420008 Kazan, Republic of Tatarstan, Russian Federation. Hector.A.Cabrera-Fuentes@biochemie.med.uni-giessen.de
authors.forename: Hector Alejandro
authors.initials: HA
authors.lastname: Cabrera-Fuentes
authors.forename: Muhammad
authors.initials: M
authors.lastname: Aslam
authors.forename: Mona
authors.initials: M
authors.lastname: Saffarzadeh
authors.forename: Alexei
authors.initials: A
authors.lastname: Kolpakov
authors.forename: Pavel
authors.initials: P
authors.lastname: Zelenikhin
authors.forename: Klaus T
authors.initials: KT
authors.lastname: Preissner
authors.forename: Olga N
authors.initials: ON
authors.lastname: Ilinskaya
mesh_terms: D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy / Q000473:pathology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001407:Bacillus / Q000201:enzymology; D016923:Cell Death / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects; D053938:DNA Fragmentation / Q000187:drug effects; D016521:Electrophoresis, Gel, Pulsed-Field; D004722:Endoribonucleases / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D012313:RNA / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D012313:RNA; D004722:Endoribonucleases; C022543:ribonuclease T(2)